Impaired development of mammary glands in scorbutic rats unable to synthesize ascorbic acid.
The effects of ascorbic acid (AsA)-deficiency on the development of mammary glands were investigated using mutant rats (osteogenic disorder syndrome rats; ODS rats) with hereditary inability to synthesize AsA. Female ODS rats of 21 days old were castrated and divided into two groups. One group was given AsA in their drinking water, and the other was not. All the rats received a daily injection of oestradiol-17 beta and progesterone (EP) from day 28 to day 49 of age. After EP treatment, the concentrations of AsA in the mammary glands of rats not given AsA were less than one tenth of those of rats given AsA and the contents of hydroxyproline in the mammary glands of the former rats were about half of those in the latter. Furthermore, the concentration of serum prolactin in rats not given AsA was reduced to about one third of that in rats given AsA. After EP treatment, whole mounts of mammary glands showed that in rats not given AsA the development of ducts was impaired and there was extensive accumulation of endbuds. Consistent with this finding, EP injections did not increase the area of parenchyma in the mammary glands of rats not given AsA, whereas they increased it about 2-fold in rats given AsA. Moreover, after EP treatment the amount of alpha-lactalbumin was significantly less in the mammary parenchyma of rats not given AsA than in that of rats given AsA. On the other hand, AsA deficiency did not impair the response of the mammary cells to insulin or prolactin in terms of DNA synthesis and alpha-lactalbumin production. These findings indicate that AsA deficiency impaired the development of mammary glands. This effect may be partly attributable to a defect in collagen synthesis in the mammary glands and a decrease in the concentration of serum prolactin.
Miyake
T
T
Department of Obstetrics and Gynecology, Osaka University Medical School, Japan.
Komura
H
H
Tokuhira
A
A
Yamamoto
T
T
Miyake
A
A
Tanizawa
O
O
Terada
N
N
Yamamoto
R
R
Yoshida
S
S
Tsuji
M
M
D000818:Animals; D001206:Ascorbic Acid Deficiency / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D001835:Body Weight; D002478:Cells, Cultured; D004958:Estradiol / Q000494:pharmacology; D005260:Female; D005346:Fibroblast Growth Factors / Q000276:immunology / Q000378:metabolism*; D006909:Hydroxyproline / Q000378:metabolism; D007074:Immunoglobulin G / Q000276:immunology; D007328:Insulin / Q000494:pharmacology; D007768:Lactalbumin / Q000378:metabolism; D008321:Mammary Glands, Animal / Q000187:drug effects / Q000254:growth & development* / Q000473:pathology; D009929:Organ Size; D010052:Ovariectomy; D011374:Progesterone / Q000494:pharmacology; D011388:Prolactin / Q000097:blood / Q000494:pharmacology; D051381:Rats; D011922:Rats, Mutant Strains; D014599:Uterus / Q000502:physiology
D007074:Immunoglobulin G; D007328:Insulin; D011374:Progesterone; D004958:Estradiol; D005346:Fibroblast Growth Factors; D011388:Prolactin; D007768:Lactalbumin; D006909:Hydroxyproline